Weight-loss drugs slash breast cancer risk by 30 in new study
A new study has found that weight-loss drugs may reduce the risk of breast cancer by up to 30%, offering a potential breakthrough in cancer prevention as obesity rates rise globally. The research, published on Thursday, suggests that medications such as GLP-1 receptor agonists—including Eli Lilly’s Mounjaro and Novo Nordisk’s Wegovy—could have secondary health benefits beyond weight management.
The study, reported by Euronews, analyzed data from women using these drugs and found a significant correlation between their use and a lower incidence of breast cancer. While the exact mechanisms remain under investigation, researchers hypothesize that the metabolic changes induced by these medications may play a role in reducing cancer risk. The findings come at a time when obesity is increasingly recognized as a major risk factor for several cancers, including breast cancer.
In Switzerland, pharmaceutical companies are ramping up awareness campaigns around obesity, a condition now linked to rising cancer rates. On March 4, digital billboards in Zurich airport displayed the message *Adipositas ist nicht Ihre Schuld* (“Obesity is not your fault”), followed by Eli Lilly’s logo—one of the leading manufacturers of obesity treatments. Similar campaigns have since appeared across Europe, from France to India, raising questions about the role of drug advertising in public health messaging. Critics argue that while these campaigns promote awareness, they also serve commercial interests, blurring the line between education and promotion .
The potential cancer-preventive effects of weight-loss drugs add urgency to ongoing debates about access and affordability. In Europe, patients and advocates have long criticized delays in making approved medications available, citing bureaucratic hurdles as a barrier to treatment. Politico Europe recently highlighted this issue, noting that while science advances rapidly, healthcare systems struggle to translate approvals into real-world access .
Meanwhile, public health officials continue to grapple with broader environmental and lifestyle factors linked to cancer. The World Health Organization (WHO) has warned that contaminated food contributes to 1.5 million deaths annually, with children particularly vulnerable. In Finland, health authorities are pushing for a ban on energy drinks for under-18s, citing concerns over addiction and malnutrition among adolescents. Spain, too, has taken action, confirming 111 cases of a rare cancer linked to textured breast implants.
As research into weight-loss drugs and cancer prevention evolves, experts stress the need for balanced regulation. While the new findings offer hope, they also underscore the complex interplay between pharmaceutical innovation, public health policy, and commercial interests. For now, the study provides a promising lead—but the path from lab to clinic remains long.
- liberation
- hvg.hu
- irish times
- independent
- nltimes.nl
- courrier international
- swissinfo
- euronews
- elmundo








